Association of genetic variations of genes encoding thrombospondin, type 1, domain-containing 4 and 7A with low bone mineral density in Japanese women with osteoporosis

AbstractTwins and family studies have shown that genetic factors are important determinants of bone mass. Important aspects of bone mineral density (BMD) regulation are endocrine systems, notably hormonal regulation of adrenal corticoids, as indicated by clinical knowledge of glucocorticoid-induced osteoporosis. Glucocorticoid is known to negatively regulate bone mass in vivo, and glucocorticoid increases thrombospondin messenger ribonucleic acid (mRNA) levels. We studied single nucleotide polymorphisms (SNPs) in genes encoding thrombospondin, type 1, domain-containing 4 and 7A (THSD4 and THSD7A) for possible association with lumbar and femoral BMD among 337 Japanese women with osteoporosis who participated in the BioBank Japan project. Genetic variations of THSD4 and THSD7A loci displayed significant association with lumbar and femoral BMD. Most significant correlation was observed for THSD7A SNP rs12673692 with lumbar BMD (P = 0.00017). Homozygous carriers of the major (G) allele had the highest BMD [0.886 ± 0.011 g/cm2, mean ± standard deviation (SD)], whereas heterozygous carriers were intermediate (0.872 ± 0.013 g/cm2) and homozygous A-allele carriers had the lowest (0.753 ± 0.023 g/cm2). THSD4 SNP rs10851839 also displayed strong association with lumbar BMD (P = 0.0092). In addition, both THSD7A and THSD4 displayed significant association with femoral BMD in a recessive model (P = 0.036 and P = 0.0046, respectively). Results suggest that variations of THSD7A and THSD4 loci may be important determinants of osteoporosis in Japanese women.

[1]  S. Inoue,et al.  A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density , 2001, Journal of Human Genetics.

[2]  J. Todd,et al.  Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. , 2000, Genome research.

[3]  C. Löwik,et al.  Effects of experimental conditions on the release of 45calcium from prelabeled fetal mouse long bones. , 1995, Bone.

[4]  B. Frenkel,et al.  Gene expression profiling of glucocorticoid-inhibited osteoblasts. , 2004, Journal of molecular endocrinology.

[5]  S. Manolagas,et al.  Role of cytokines in bone resorption. , 1995, Bone.

[6]  Kay Dickersin,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.

[7]  Hajime Orimo,et al.  Diagnostic criteria for primary osteoporosis: year 2000 revision , 2001, Journal of Bone and Mineral Metabolism.

[8]  Yao-Zhong Liu,et al.  Molecular studies of identification of genes for osteoporosis: the 2002 update. , 2003, The Journal of endocrinology.

[9]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[10]  F. Buttgereit,et al.  Molecular mechanisms of glucocorticoid-induced osteoporosis. , 2001, Bone.

[11]  S. Ralston,et al.  Genetic determinants of susceptibility to osteoporosis. , 2003, Endocrinology and metabolism clinics of North America.

[12]  M. Cohen-Solal,et al.  [Genetics of osteoporosis]. , 2004, La Revue de medecine interne.

[13]  S. Lamberts,et al.  Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. , 2004, Recent progress in hormone research.

[14]  M. Cohen TGFβ/Smad signaling system and its pathologic correlates , 2003 .

[15]  M. Cohen TGF beta/Smad signaling system and its pathologic correlates. , 2003, American journal of medical genetics. Part A.

[16]  Geoffrey D. Young,et al.  The Tryptophan-rich Motifs of the Thrombospondin Type 1 Repeats Bind VLAL Motifs in the Latent Transforming Growth Factor-β Complex* , 2004, Journal of Biological Chemistry.